|
시장보고서
상품코드
2102547
탈라조파립 시장 규모, 점유율 및 성장 분석 : 적응증별, 치료법별, 치료 단계별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Talazoparib Market Size, Share, and Growth Analysis, By Indication, By Therapy Type, By Line of Therapy, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 탈라조파립 시장 규모는 2024년에 5억 달러로 평가되며, 2025년 5억 5,250만 달러에서 2033년까지 12억 2,810만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 10.5%로 성장할 것으로 전망되고 있습니다.
전 세계 탈라조파립 시장은 주로 생식세포 계통 BRCA 변이를 가진 HER2 음성 유방암 환자를 대상으로 한 선택적 PARP 억제제를 중심으로 전개되고 있습니다. 그 중요성은 합성 치사성을 통해 무재발 생존 기간을 연장할 수 있다는 점과, 정맥 주사에 비해 독성이 낮은 경구 투여 옵션이 제공된다는 데 있습니다. 이 시장은 그 유효성을 지원하는 RWD(Real World Data)에 힘입어 전문 약국에서 일반 종양학 처방집으로 확대되고 있습니다. 또한 적응증이 난소암 및 췌장암으로 확대되고 있으며, 면역관문 억제제와의 병용에 따른 시너지 효과를 입증하는 임상시험이 정교화되고 있는 점도 시장 성장을 지원하고 있습니다. AI를 활용한 환자 선별은 치료 전략에 혁명을 일으키고, 임상시험 피험자 모집을 최적화하며, 임상 결과를 개선하고 있으며, 궁극적으로 탈라조파립의 더 광범위한 채택을 촉진하고 현대 종양학에서 필수적인 요소로서의 입지를 확립하는 데 기여할 것입니다.
전 세계 탈라조파립 시장의 성장 요인
다양한 종양 유형에서 탈라조파립의 유효성을 입증하는 임상적 근거가 증가함에 따라 종양 전문의들은 유방암이라는 주요 적응증을 넘어 이 약물의 사용을 고려하게 되었고, 그 결과 잠재적 환자층이 확대되고 있습니다. 의사들이 병용 요법에 이 약물을 포함시키는 데 자신감을 갖게 됨에 따라 의료 시스템 내에서도 확립된 치료 프로토콜에 이 약물이 포함되고 있습니다. 이러한 추세는 수요를 크게 끌어올려 시장 성장을 촉진하고 있습니다. 또한 탈라조파립의 용도 확대에 따라 제약 업계내 연구 협력이 강화되고, 임상의에 대한 교육 지원 및 보험 급여 협상이 개선되고 있으며, 이 모든 요소가 채택 확대와 시장 발전이라는 선순환을 지원하고 있습니다.
전 세계 탈라조파립 시장의 제약 요인
표준 치료법에 비해 탈라조파립의 높은 비용은 병원이나 보험사에 재정적 부담을 주게 되며, 그 결과 보험 적용 리스트 등재가 제한되거나 사전 승인 절차가 마련되고 있습니다. 보험사는 BRCA 변이가 확인된 환자나 치료 후기 단계에 있는 환자 등 특정 환자 그룹에만 보험 적용을 제한하는 경우가 있으며, 이로 인해 잠재적 시장 규모가 축소됩니다. 그 결과, 효능 차이가 극히 미미한 경우 의료 서비스 제공자가 더 저렴한 대체 약물을 선택할 가능성이 있으며, 이는 탈라조파립의 전반적인 채택을 저해하고 제조사의 수익 성장을 제한하게 됩니다. 이러한 재정적 제약으로 인해 일부 의료 기관은 조기 치료 프로토콜에 이 약물을 포함시키는 것을 주저하게 되어, 시장 진전을 더욱 지연시키는 결과로 이어집니다.
전 세계 탈라조파립 시장 동향
전 세계 탈라조파립 시장에서는 개인 맞춤형 암 치료 접근법의 부상이라는 혁신적인 동향이 나타나고 있습니다. 유전체 프로파일링 및 동반 진단의 발전에 따라 임상의들은 기존의 BRCA 돌연변이에 국한되지 않고 특정 DNA 복구 결함을 보이는 환자에게 탈라조파립 요법을 개별적으로 적용하는 것이 점점 더 가능해지고 있습니다. 이러한 정밀 의학에 대한 집중은 적격 환자군을 확대할 뿐만 아니라, 조기 개입을 촉진하고 종양학 분야의 공동 연구와 혁신을 지원하고 있습니다. 제약 파트너사들은 바이오마커 기반의 임상시험 설계를 채택하고 있으며, 의료 서비스 제공자들은 개인 맞춤형 치료 경로를 중시함으로써 치료 성과와 환자 만족도 향상을 도모하고 있습니다. 이러한 변화는 처방 관행을 재구성하고, 전 세계 다양한 종양학 적응증에서 탈라조파립의 통합을 촉진하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 탈라조파립 시장 규모 : 적응증별
세계의 탈라조파립 시장 규모 : 요법 유형별
세계의 탈라조파립 시장 규모 : 치료 단계별
세계의 탈라조파립 시장 규모 : 유통 채널별
세계의 탈라조파립 시장 규모 : 최종사용자별
세계의 탈라조파립 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.08.05Global Talazoparib Market size was valued at USD 500.0 Million in 2024 and is poised to grow from USD 552.5 Million in 2025 to USD 1228.1 Million by 2033, growing at a CAGR of 10.5% during the forecast period (2026-2033).
The global Talazoparib market is centered on a selective PARP inhibitor primarily targeting patients with germline BRCA-mutated, HER2-negative breast cancer. Its significance lies in its ability to enhance progression-free survival through synthetic lethality, with an oral administration option that offers a less toxic alternative to intravenous treatments. The market has seen expansion from specialty pharmacies to mainstream oncology formularies, driven by real-world evidence reinforcing its efficacy. Growth is further propelled by expanding indications into ovarian and pancreatic cancers and the refinement of clinical trials demonstrating its synergistic benefits in combination with immune checkpoint inhibitors. AI-driven patient selection is revolutionizing treatment strategies, optimizing trial recruitment, and enhancing clinical outcomes, ultimately facilitating broader adoption and establishing Talazoparib as a vital component of modern oncology.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Talazoparib market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Talazoparib Market Segments Analysis
Global talazoparib market is segmented by indication, therapy type, line of therapy, distribution channel, end user and region. Based on indication, the market is segmented into HER2-Negative Breast Cancer, BRCA-Mutated Breast Cancer, Metastatic Castration-Resistant Prostate Cancer and Others. Based on therapy type, the market is segmented into Monotherapy, Combination Therapy, Maintenance Therapy and Others. Based on line of therapy, the market is segmented into First-Line, Second-Line, Third-Line & Later and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies and Others. Based on end user, the market is segmented into Hospitals, Oncology Centers, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Talazoparib Market
The increasing clinical evidence demonstrating the efficacy of talazoparib in various tumor types is prompting oncologists to explore its use beyond its primary indication for breast cancer, thereby expanding the potential patient base. As physicians gain confidence in incorporating the drug into combination therapies, healthcare systems are incorporating it into established treatment protocols. This trend significantly boosts demand and facilitates market growth. Additionally, the expanded use of talazoparib is leading to enhanced collaborations within the pharmaceutical industry for research, supporting initiatives to educate clinicians, and improving reimbursement negotiations, all of which contribute to a reinforcing cycle of increased adoption and market development.
Restraints in the Global Talazoparib Market
The high cost of talazoparib compared to standard treatment options imposes financial strain on hospitals and insurance companies, leading to restricted formulary access and prior authorization procedures. Payers may limit coverage to specific patient groups, such as those with identified BRCA mutations or those in later stages of therapy, which reduces the potential market size. As a result, healthcare providers may choose more affordable alternatives when the efficacy differences are minimal, hindering the overall adoption of talazoparib and limiting revenue growth for manufacturers. This financial constraint also dissuades some healthcare institutions from incorporating the drug into early-stage treatment protocols, further stalling market progress.
Market Trends of the Global Talazoparib Market
The Global Talazoparib market is witnessing a transformative trend characterized by the rise of personalized oncology approaches. With advancements in genomic profiling and companion diagnostics, clinicians are increasingly able to tailor talazoparib therapy to patients exhibiting specific DNA repair deficiencies that extend beyond traditional BRCA mutations. This precision medicine focus not only broadens patient eligibility but promotes earlier interventions, fostering collaborative research and innovation within the oncology field. Pharmaceutical partners are adopting biomarker-driven trial designs, while healthcare providers emphasize personalized treatment pathways, thereby improving therapeutic outcomes and patient satisfaction. This shift is reshaping prescribing practices and driving the integration of talazoparib across various oncology indications globally.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Talazoparib Market Size by Indication & CAGR (2026-2033)
- Market Overview
- HER2-Negative Breast Cancer
- BRCA-Mutated Breast Cancer
- Metastatic Castration-Resistant Prostate Cancer
- Others
Global Talazoparib Market Size by Therapy Type & CAGR (2026-2033)
- Market Overview
- Monotherapy
- Combination Therapy
- Maintenance Therapy
- Others
Global Talazoparib Market Size by Line of Therapy & CAGR (2026-2033)
- Market Overview
- First-Line
- Second-Line
- Third-Line & Later
- Others
Global Talazoparib Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
- Others
Global Talazoparib Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Oncology Centers
- Specialty Clinics
- Others
Global Talazoparib Market Size & CAGR (2026-2033)
- North America (Indication, Therapy Type, Line of Therapy, Distribution Channel, End User)
- US
- Canada
- Europe (Indication, Therapy Type, Line of Therapy, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Indication, Therapy Type, Line of Therapy, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Indication, Therapy Type, Line of Therapy, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Indication, Therapy Type, Line of Therapy, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GSK plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BeiGene, Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zai Lab Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BridgeBio Pharma, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Repare Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- IDEAYA Biosciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Artios Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allarity Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Clovis Oncology, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exelixis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
